Tianjin Lisheng Pharmaceutical Co Ltd Market Cap ($592.33 Million)
Market Cap & Net Worth: Tianjin Lisheng Pharmaceutical Co Ltd (002393)
Tianjin Lisheng Pharmaceutical Co Ltd market cap. Tianjin Lisheng Pharmaceutical Co Ltd (SHE:002393) has a market capitalization of $592.33 Million (CN¥4.05 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #11070 globally and #3018 in its home market, demonstrating a 4.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tianjin Lisheng Pharmaceutical Co Ltd's stock price CN¥13.13 by its total outstanding shares 308293069 (308.29 Million). Also see cash flow conversion of Tianjin Lisheng Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Tianjin Lisheng Pharmaceutical Co Ltd Market Cap History (2015–2026)
Tianjin Lisheng Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $1.38 Billion to $592.33 Million (-4.93% CAGR). Check 002393 stock price for real-time trading data and today's change.
Tianjin Lisheng Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tianjin Lisheng Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Tianjin Lisheng Pharmaceutical Co Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.70x
Tianjin Lisheng Pharmaceutical Co Ltd's market cap is 0.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.34x
Tianjin Lisheng Pharmaceutical Co Ltd's market cap is 2.34 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.19 Billion | $846.85 Million | $115.61 Million | 1.41x | 10.33x |
| 2017 | $913.26 Million | $1.03 Billion | $116.82 Million | 0.89x | 7.82x |
| 2018 | $634.65 Million | $1.50 Billion | $184.98 Million | 0.42x | 3.43x |
| 2019 | $815.92 Million | $1.62 Billion | $188.14 Million | 0.51x | 4.34x |
| 2020 | $615.43 Million | $1.14 Billion | $8.62 Million | 0.54x | 71.43x |
| 2021 | $655.66 Million | $1.09 Billion | $122.11 Million | 0.60x | 5.37x |
| 2022 | $655.38 Million | $1.15 Billion | $93.61 Million | 0.57x | 7.00x |
| 2023 | $813.47 Million | $1.15 Billion | $361.83 Million | 0.71x | 2.25x |
| 2024 | $795.79 Million | $1.34 Billion | $184.53 Million | 0.60x | 4.31x |
| 2025 | $979.40 Million | $1.39 Billion | $418.37 Million | 0.70x | 2.34x |
Competitor Companies of 002393 by Market Capitalization
Companies near Tianjin Lisheng Pharmaceutical Co Ltd in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Tianjin Lisheng Pharmaceutical Co Ltd for a full breakdown of the balance sheet.
Key companies related to Tianjin Lisheng Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Tianjin Lisheng Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Tianjin Lisheng Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Tianjin Lisheng Pharmaceutical Co Ltd's market cap moved from $1.38 Billion to $ 592.33 Million, with a yearly change of -4.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥592.33 Million | -39.52% |
| 2025 | CN¥979.40 Million | +23.07% |
| 2024 | CN¥795.79 Million | -2.17% |
| 2023 | CN¥813.47 Million | +24.12% |
| 2022 | CN¥655.38 Million | -0.04% |
| 2021 | CN¥655.66 Million | +6.54% |
| 2020 | CN¥615.43 Million | -24.57% |
| 2019 | CN¥815.92 Million | +28.56% |
| 2018 | CN¥634.65 Million | -30.51% |
| 2017 | CN¥913.26 Million | -23.51% |
| 2016 | CN¥1.19 Billion | -13.49% |
| 2015 | CN¥1.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Tianjin Lisheng Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $592.33 Million USD |
| MoneyControl | $592.33 Million USD |
| MarketWatch | $592.33 Million USD |
| marketcap.company | $592.33 Million USD |
| Reuters | $592.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive sy… Read more